Skip to content
Notification Image

Important! APA's Online Systems Updated.

Password reset will be required.

Read more here >

APA Blogs

Listing will update automatically when filter selections change

243 Results

March 23, 2022

Cataract Surgery and Hearing Aids May Help Reduce the Risk of Dementia in Older Adults

  • Patients and Families

Dementia affects an estimated 50 million people worldwide and about 4 million in the U.S., about 9% of adults 65 or older. In the past, several factors have been identified that reduce the risk of dementia, including educational level, high blood pressure, diabetes mellitus, obesity, smoking, sedentary lifestyle, depression, social isolation. Recent research says that in older adults, treatments for hearing and vision problems can also help reduce the risk of dementia.

March 16, 2022

Caring for Pregnant Women: A Psychiatrist’s Guide

Every psychiatrist will see a pregnant woman or other patient who is pregnant someday. When that person presents to your office, will you be ready? Many of us received little if any training on the subject, so the American Psychiatric Association’s Committee on Women’s Mental Health would like to help. Read on for five things every psychiatrist needs to know before a pregnant patient walks in your door.

March 11, 2022

New Report Examines Disparities in Dementia Care

  • Alzheimer’s, Patients and Families

A new report from the Alzheimer’s Association finds that non-white racial/ethnic populations expect and experience more barriers when accessing dementia care and report having less trust in medical research than white Americans. “Race, Ethnicity and Alzheimer’s in America,” is a companion report to the Association’s annual Facts and Figures report.

March 11, 2022

What APA Is Doing for You: Update on Clozapine REMS

  • By Saul Levin, M.D., M.P.A., FRCP-E, FRCPsych
  • CEO Blog, Schizophrenia, What APA is Doing For You

In November 2021, the Food and Drug Administration (FDA) instituted a new Clozapine Risk Evaluation and Mitigation Strategy (REMS) to monitor prescribing and dispensing of the drug, which is used to treat schizophrenia. The new REMS led to confusion for manufacturers, pharmacies, prescribers, and patients. Some clinicians stopped prescribing the already underutilized drug, and some pharmacies stopped dispensing it. This chaotic situation led the FDA to stop enforcing certain requirements of the REM for 90 days.

Medical leadership for mind, brain and body.

Join Today